Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
RecruitingObservational study
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients with lymphoma that are fulfilling at least one of the following: A. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25\>3,900 U/mL and ferritin\>1,000 ng/mL) Exclusion Criteria: * Patients developing HLH\> 1 month after lymphoma diagnosis (for aggressive lymphomas) * Patients with incomplete treatment and response documentation
About the study
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
Sponsor: University of Alabama at Birmingham · Participants: 2,000 · Started: May 1, 2023
Contact the study team
- Gaurav Goyal, MD · Phone: 205-934-1816
Official record on ClinicalTrials.gov — NCT05898477
Locations in the U.S.
| Alabama | University of Alabama at Birmingham, Birmingham |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.